4D Molecular Therapeutics’ (FDMT) “Buy” Rating Reaffirmed at Chardan Capital

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $25.00 price target on the stock.

FDMT has been the topic of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of 4D Molecular Therapeutics in a report on Friday, June 27th. The Goldman Sachs Group dropped their target price on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Bank of America dropped their target price on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Finally, Barclays dropped their target price on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.56.

4D Molecular Therapeutics Trading Down 5.0%

Shares of FDMT stock opened at $4.10 on Thursday. 4D Molecular Therapeutics has a 12 month low of $2.24 and a 12 month high of $28.93. The stock has a market cap of $189.72 million, a PE ratio of -1.29 and a beta of 2.81. The company’s fifty day moving average price is $3.78 and its 200-day moving average price is $4.22.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 767,126.06% and a negative return on equity of 33.26%. On average, sell-side analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several large investors have recently modified their holdings of FDMT. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics in the 1st quarter worth about $39,000. Y Intercept Hong Kong Ltd purchased a new position in 4D Molecular Therapeutics in the 1st quarter worth about $41,000. AQR Capital Management LLC purchased a new position in 4D Molecular Therapeutics in the 1st quarter worth about $46,000. KLP Kapitalforvaltning AS purchased a new position in 4D Molecular Therapeutics in the 4th quarter worth about $48,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in 4D Molecular Therapeutics in the 4th quarter worth about $50,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.